I am a biologist always excited to contribute to the discovery of new treatments. I received a BA in Biochemistry and Molecular Biology as well as a Master of Public Health from Boston University. I began my scientific career at Beth Israel Deaconess Medical Center developing antibodies for NHP models of disease. Following this role, I joined Editas Medicine, a CRISPR company, where I looked at Cas9 biology and contributed to the genotoxicity assessments for several IND-enabling programs. Prior to joining Entact Bio, I supported target validation efforts in the muscle and oncology programs at Faze Medicines, a biomolecular condensate start up.